Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · IEX Real-Time Price · USD
16.55
+0.21 (1.29%)
At close: Jul 2, 2024, 4:00 PM
16.59
+0.04 (0.24%)
After-hours: Jul 2, 2024, 7:51 PM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $16.00B in the twelve months ending March 31, 2024, with 7.22% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $3.82B with 4.32% year-over-year growth. In the year 2023, Teva Pharmaceutical had annual revenue of $15.85B with 6.17% growth.
Revenue (ttm)
$16.00B
Revenue Growth
+7.22%
P/S Ratio
1.17
Revenue / Employee
$422,816
Employees
37,851
Market Cap
18.74B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
Dec 31, 2005 | 5.25B | 451.00M | 9.40% |
Dec 31, 2004 | 4.80B | 1.52B | 46.47% |
Dec 31, 2003 | 3.28B | 757.80M | 30.09% |
Dec 31, 2002 | 2.52B | 441.20M | 21.24% |
Dec 31, 2001 | 2.08B | 327.50M | 18.72% |
Dec 31, 2000 | 1.75B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molina Healthcare | 35.85B |
Koninklijke Philips | 20.19B |
Labcorp Holdings | 12.30B |
Zimmer Biomet Holdings | 7.45B |
STERIS | 5.14B |
Hologic | 3.96B |
Align Technology | 3.92B |
The Cooper Companies | 3.73B |
TEVA News
- 7 hours ago - Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024 - Business Wire
- 1 day ago - Teva's stock falls after report FTC has opened probe of patents - Market Watch
- 1 day ago - FTC starts probe into Teva about some products' patents, Washington Post reports - Reuters
- 4 days ago - New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses - Business Wire
- 7 days ago - Teva settles tax dispute in Israel with $750 mln payment - Reuters
- 7 days ago - Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020 - Business Wire
- 8 days ago - Teva launches generic version of Novo Nordisk's diabetes drug Victoza - Reuters
- 8 days ago - Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States - Business Wire